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A SEQUENTIAL STUDY OF CIRCULATING IMMUNE COMPLEXES,
COMPLEMENT AND IMMUNOGLOBULINS IN BORDERLINE
TUBERCULOID LEPROSY PATIENTS WITH AND WITHOUT REACTIONS
VD Ramanathan, P Thyagi, U Ramanathan, K Katoch, G Ramu
Sequential estimates of the levels of circulating immune complexes (CIC), complement
catabolic fragment C3d, complement-mediated immune complex solubilization (CMS) and
immunoglobulins were made in 24 newly diagnosed patients with borderline tuberculoid
leprosy over a 20 month period after initiation of chemotherapy.
Fourteen of these patients had not suffered from reversal reactions either at the time
of presentation or during the follow-up period. The levels of CIC were elevated in them
from the third to the eleventh month after starting chemotherapy and immunoglobulin G
(IgG) levels were elevated upto eight months. The concentrations of C3d and
immunoglobulins A (IgA) and M (IgM) were normal in these patients.
The other ten patients had reversal reaction at the time of diagnosis which subsided
by the third month after starting treatment. They did not have reversal reactions later. The
levels of CIC and IgG were elevated and those of CMS were depressed throughout the
study period. Serum C3d level was initially elevated but came down to normal by the third
month while IgA and IgM levels were within normal limits.
The relevance of these findings to the genesis of reversal reaction is discussed in this
communication.
INTRODUCTION
Antigen-antibody complexes or immune complexes (ICs) are thought to play a vital
role in the occurrence of erythema nodosum leprosum (ENL) syndrome in leprosy. It is held
that an increase in lymphocyte-mediated delayed hypersensitivity results in the production
of the reversal (type 1) reaction. However, perturbations in complement and antibody levels
during type 1 reaction suggest that ICs may be involved in the causation of some of the
manifestations of this condition also (Ramanathan et al 1985, Chakrabarty et al 1988, Saha
et al 1995).
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We had earlier found that circulating ICs (CICs) and complement catabolic fragment
(C3d) were elevated during reactions in borderline tuberculoid leprosy (BT) patients
(Ramanathan et al 1984). Further, it was noted that such patients had a lowered complement
-mediated IC solubilization (CMS) (Ramanathan et al 1985, Chakrabarty et al 1988). Efficient
solubilization by complement renders ICs innocuous by making them incapable of stimulating
phlogistic responses, and this function of the complement system is thought to reflect the
ability of individuals to metabolize ICs in vivo.
In order to better define the relationship between the humoral immune parameters and
the occurrence of reversal reactions, we decided to sequentially estimate the levels of CICs,
immunoglobulins, C3d and complement-mediated IC solubilization (CMS) in a group of
untreated BT leprosy patients and follow them up for some time after initiating treatment.
MATERIAL AND METHOD
SUBJECTS
The subjects consisted of patients and controls. Twenty-four untreated adult BT patients
(18 males and six females) diagnosed on the basis of Ridley-Jopling criteria (Ridley &
Jopling 1966) were the subjects for this study. Their mean ages and durations of the disease
at the time of presentation are given in Table I. They were put on multidrug regimen as per
the schedule prescribed by the National Leprosy Eradication Programme (NLEP) of India
(IAL 1984). Blood was collected from them at the time of inception of treatment, two
months after starting chemotherapy and subsequently at three-monthly intervals up to 20
months.
Table I. Clinical features of borderline tuberculoid (BT) patients without and with (BTR) reactions at the
time of presentation
Type
of
disease
Mean age Disease duration Lepromin reaction (mm)
M/F (Years) at presentation
± SD (years) Erythema Induration
BT 11/3 34.0 ± 12.2 2.29 ± 1.35 7.9 ± 4.0 2.57 ± 1.27
BTR 7/3 42.2 ± 16.7 3.31 ± 3.43 13.0 ± 6.0 3.11 ± 1.45
Twenty-four healthy laboratory volunteers and hospital staff of the Central JALMA
Institute for Leprosy (Agra), matched for age and sex were used as control subjects. Sera
from at least three of them were tested along with those of the patients in all the investigations.
Serum pooled from a minimum of five volunteers (NHS) was used as the standard.
SERUM
Blood was collected from the patients and the controls and the separated serum was
stored at -70 °C in aliquots. Each aliquot was used only once after thawing.
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LEPROMIN TESTING
Patients were given intradermally 0.1 ml of standardized Dharmendra lepromin
(Sengupta et al 1979) in the volar aspect of the forearm. Both erythema and induration were
measured 24 hr after the test.
MATERIALS
Bovine conglutinin was prepared as described by Lachmann and Hobart (1978) from
normal bovine serum which was kindly supplied by Dr VD Padmanabhan, Madras Veterinary
College, Chennai. Conglutinin and bovine serum albumin (BSA) were labelled with 125I
(Bhabha Atomic Research Centre, Mumbai), using iodogen (Hudson & Hay 1980). Antiserum
against BSA was raised in rabbits. Antisera against C3d (Dakopatts, Denmark) and
immunoglobulins G, A and M (Hoechst India Ltd) were purchased as indicated.
METHOD
Circulating ICs, complement-mediated IC solubilization (CMS), serum C3d and
immunoglobulins were measured as indicated. Circulating ICs were estimated using
125I-labelled conglutinin as described previously (Ramanathan et al 1984). Conglutinin was
prepared, as suggested by Lachmann and Hobart (1978) from normal bovine serum (obtained
from Madras Veterinary College, Chennai 7). The result was expressed as a number obtained
by dividing conglutinin binding in the patient’s serum by the binding in the pooled normal
serum run the same day as control (Ramanathan et al 1991).
Complement-mediated IC solubilization was performed using 125I-labelled bovine serum
albumin (BSA)-anti BSA immune complexes. The amount of ICs solubilized was expressed
as a proportion of the ICs solubilized in the pooled serum control included in the same
batch (Ramanathan et al 1985, 1991).
Complement C3d levels were quantitated with a two-stage procedure involving
precipitation with 22% polyethyelene glycol and rocket immuno electrophoresis using
anti-C3d antiserum (Dakopatts, Denmark). The results were measured as “arbitrary Units”
(aU) which were derived from the standard C3d generated in pooled NHS treated with
20mg/ml yeast at 37 °C for two hours (Ramanathan et al 1984).
Serum immunoglobulins G, A and M were measured using immunoglobulin class
-specific antisera (Hoechst India Ltd, India) by the single radial immunodiffusion procedure.
ANALYSIS OF RESULTS
The results were analysed at the end of the study period, after completing all the
laboratory tests, to avoid bias. Student’s two-tailed unpaired t-test was used for inter-group
comparisons. The paired t-test was used for comparisons within a group at different periods
relative to a fixed time point.
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CLINICAL FEATURES OF REACTIONS
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Of the 24 patients, ten had features of reactions (consisting mainly of erythema and
oedema of the lesions) which were the presenting symptoms in these patients. There was
a tendency for an increased occurrence of neuritis in these patients (4/10) compared to
patients without reaction (2/14) but, this difference was not statistically significant.
Chloroquine and aspirin were given to control reactions and when there was neuritis, that
was treated with corticosteroids. These drugs were discontinued after the subsidence of the
reaction. The reaction usually subsided by three months and these patients did not suffer
from any more episodes during the follow-up period. When patients were tested with
Dharmendra lepromin, at 24 hours, slightly greater erythema (p>0.05) was seen in BTR
patients (Table I).
CIRCULATING IMMUNE COMPLEXES
The levels of CIC in the patients are expressed as a fraction of the levels observed
in normal human serum (NHS). We found that there was an increase in their levels in BT
patients without reactions from the third month onwards upto the eleventh month which
then came down to levels comparable to those observed in NHS by the fourteenth month
after initiation of treatment. The CIC levels of BTR patients were elevated throughout the
period of study, even after the subsidence of reactions (Fig. 1).
Fig. 1. Levels of circulating immune complexes in the non-reactional and reactional patients expressed as an index
(Mean ± 95% CI). Horizontal box indicates the 95% CI of values seen in normal human serum.
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The mean C3d in NHS was 3.17 aU/ml (95% confidence interval: 0.99 to 5.35). The
concentrations of C3d in both groups of patients (BT and BTR) were estimated only up to
the fourteenth month. The levels of serum C3d (Table II) and CMS (Fig. 2) in the non
-reactional BT patients were within normal limits. On the other hand, there were alterations
in both C3d and CMS levels in BTR patients. Serum C3d which was elevated at the onset
of reaction, was not significantly different from normal levels by the second month after the
initiation of antileprosy treatment. However, the ability to solubilize ICs through the
complement system consistently remained low compared to NHS.
Table II. Levels of C3d in patients expressed as aU/ml
Month
Mean
BT BTR
95% CI Mean 95% CI
0 5.63 3.15 - 8.11 16.4 11.13 - 21.67
2 4.81 1.94 - 7.72 10.8 0.79 - 20.87
5 6.41 2.49 - 10.33 15.0 0.14 - 30.14
8 2.49 0.87 - 4.11 4.3 0.29 - 8.87
11 3.64 2.32 - 4.96 14.3 0.71 - 37.21
14 10.50 0.24 - 21.24 6.0 0.11 - 11.89
95% CI = 95% confidence interval. Value in normal serum was 3.17 aU/ml.
(95% CI = 0.99-5.35)
Fig. 2. Levels of complement-mediated immune complex solubilization in non-reactional and reactional patients.
Results are expressed as percentage of solubilization seen in pooled normal human serum (mean ± 95% CI).
Horizontal box indicates the 95% CI of values in normal human serum.
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IMMUNOGLOBULINS
The levels of IgG which were significantly elevated to begin with, returned to normal
levels from the eighth month onwards, in the non-reactional BT patients. In the BTR
patients, they were elevated throughout the period of observation (Fig. 3).
Fig. 3. Levels of immunoglobulin G in the non-reactional and reactional patients (Mean ± 95% CI). Horizontal
box indicates the 95% CI of values seen in normal human serum.
The levels of immunoglobulins A and M were largely unaltered in both groups of
patients and were comparable with those of NHS (data not shown).
DISCUSSION
This is a long-term follow-up study of serum immune complexes and complement
activation in BT patients with and without reaction following treatment. The findings of the
present study are in agreement with those made earlier that reactional states are seen only
in a proportion of the leprosy patients and that elevated CICs and complement catabolic
fragments are noted during such states (Saha et al 1982, Ramanathan et al 1984, 1985).
Further, this is accompanied by a lowered capacity to solubilize preformed ICs. This
reduced solubilization persists even after evidence for complement activation (indicated by
increased C3d) was absent in the circulation (Fig. 2 and Table II). Although the mean levels
of C3d in the BT patients at the fourteenth month and in the BTR patients at the eleventh
month were high, they were not significantly different from that in the normal serum. As
anti-reaction treatment with steroids was terminated three months after subsidence of reaction,
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the persistently reduced CMS cannot be attributed to the effect of these drugs (Packard &
Weiler 1983). Similarly, as these patients were treated with rifampicin and DDS only, the
anticomplementary effect of clofazimine (Saha et al 1982) cannot be the reason for the
persistant reduction of CMS.
Reversal (type 1) reactions in BT leprosy patients are conventionally attributed to an
increase in delayed hypersensitivity response. However, there are reports of perturbation in
the humoral immune system in patients undergoing reversal reactions. These mainly involve
an increase in immunoglobulins and antibody levels (Lanjendijk et al 1983) increase in CIC
and C3d and a depressed CMS (Ramanathan et al 1984, 1985, Chakrabarty et al 1988).
Recently, it has been reported by Saha and his co-workers (1995) that anti-PGL antibodies
of IgG class remain elevated even after the subsidence of reversal reaction. The findings
presented in this study further confirm these reports.
When BT reactional lesions are examined histologically, lymphocytes, epithelioid
cells, giant cells and plasma cells are seen. This would imply that cell-mediated
hypersensitivity plays a major role in the genesis of reversal reactions. However, in view
of the findings reported here and the presence of 20% B lymphocytes documented by Nilsen
and his coworkers (1986) in nerve lesions in BT patients, it is clear that humoral mechanisms
also play an important role in the causation of this type of reactions. Since a persistently
reduced CMS appears to be a distinguishing feature of reactions in leprosy, the following
explanation could account for the findings.
The immune complexes which are formed in situ are not cleared due to poor
complement-mediated solubilization. It is known that unsolubilized complexes are capable
of binding to various cellular receptors (Takahashi et al 1980, Law & Dodds 1997). It was
noted in the present study that although the CIC levels were elevated in the non-reactional
BT patients, since the CMS capacity remained intact it is likely that CICs had been fully
solubilized and therefore were not pathogenic. The unsolubilized complexes in the reactional
BT patients probably stimulate T cells which are responsible for delayed hypersensitivity.
Although further proof is necessary for substantiating this hypothesis, it can be used as a
working premise from which to proceed further to understand the pathogenesis of reversal
reactions.
ACKNOWLEDGEMENT
We thank Dr VD Padmanabhan of Madras Veterinary College, Chennai 7 for providing normal bovine
serum which was used for the preparation of conglutinin.
REFERENCES
1. Chakrabarty AK, Kashyap A, Sehgal VN, Saha K 1988. Solubilization of preformed immune
complexes in sera of patients with type 1 and type 2 lepra reactions. Int J Lepr 56: 559-565.
2. Hudson L, Hay FC 1980. Practical Immunology, Oxford, Blackwell Scientific Publications,
p 243.
159
Indian J Lepr Vo1. 70(2) 1998
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
IAL, 1984. Summary of the seminar on consensus on treatment regimens in leprosy and problems
of drug delivery. Indian J Lepr 56: 158-159.
Lachmann PJ, Hobart MJ 1978. Complement technology. In Handbook of Experimental
Immunochemistry, ed DM Weir, Oxford, Blackwell Scientific Publications, p 54-57.
Lanjendijk EJMT, van Diepen TW, Harboe M, Belehu A 1983. Relation between
anti- Mycobacterium leprae antibody activity and clinical features in borderline tuberculoid
(BT) leprosy. Int J Lepr 51: 305-311.
Law SK, Dodds AW 1997. The internal thioester and the covalent binding properties of the
complement proteins C3 and C4. A review. Protein Science 6: 263-274.
Nilsen R, Mshana RN, Negesse Y et al 1986. Immunohistochemical studies of leprous neuritis.
Lepr Rev 57: (Suppl 2) 177-187.
Packard BD, Weiler JM 1983. Steroids inhibit the activation of the alternative amplification
pathway of complement. Infect Immun 40: 1011-1014.
Ramanathan VD, Parkash O, Ramu G et al 1984. Isolation and analysis of circulating immune
complexes in leprosy. Clin Immunol Immunopathol 32: 261-268.
Ramanathan VD, Sharma P, Ramu G, Sengupta U 1985. Reduced complement-mediated immune
complex solubilization in leprosy patients. Clin Exp Immunol 60: 553-558.
Ramanathan VD, Tyagi P, Ramanathan U et al 1991. Persistent reduced solubilization of
immune complexes in lepromatous patients with reactions. Int J Lepr 59: 5-11.
Ridley DS, Jopling WH 1966. Classification of leprosy according to immunity. A five group
system. Int J Lepr 34: 255-273.
Saha K, Chakrabarty AK, Sharma V, Sehgal VN 1982. An appraisal of third complement
component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL). Lepr
Rev 53: 253-260.
Saha K, Chattopadhya D, Kashyap A et al 1995. Enhanced response of serum IgG class of anti
-PGL 1 antibodies in leprosy patients during onset and following clinical remission of type 1
and type 2 reactions. Int J Lepr 63: 105-108.
Sengupta U, Ramu G, Desikan KV 1979. Assessment of Dharmendra antigen. Standardization
of the antigen. Lepr India 51: 316-329.
Takahashi M, Takahashi S, Hirose S 1980. Solubilization of antigen-antibody complexes. A
new function of complement as a regulator of immune reactions. Prog Allergy 27: 134-166.
160
